Skip to main content
XENE logo

Xenon Pharmaceuticals Inc.

XENENASDAQHealthcareBiotechnology

$34.33Today:- (-)1Y −18.59%

As of Oct 15, 2026 close

Market cap
$3.42B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$33.52$72.66
Volume (live)
-
Avg. volume (3M)
2.28M

Xenon Pharmaceuticals (XENE) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Xenon Pharmaceuticals used $279.12M of cash in operating activities and spent $799.00K on capital expenditures. That left free cash flow of −$279.92M.

Xenon Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Xenon Pharmaceuticals Inc. (XENE) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-345.91-234.33-182.39-125.37-78.88-28.84-41.60-34.50-30.70
Depreciation & Amortization2.542.562.061.620.910.640.430.590.65
Deferred Income Tax-3.20-8.86-0.29-0.040.06-0.29-0.130.65-1.47
Stock Based Compensation53.7150.7232.3720.3810.025.682.922.632.24
Change in Working Capital4.365.715.90-0.68-2.65-26.0933.520.030.56
Change in Accounts Receivable0.10-0.610.131.76-0.46-1.03-0.650.18-0.23
Change in Inventory0.000.000.000.00-2.97-2.02-4.54-0.780.61
Change in Accounts Payable5.518.533.938.062.972.024.540.780.00
Change in Other Working Capital1.311.251.21-10.50-2.19-0.2734.17-0.150.18
Other Operating Activities1.311.251.215.661.050.270.22-4.110.01
Net Cash from Operating Activities-279.12-181.39-151.11-98.43-69.50-48.12-4.63-34.72-28.73
Investing Activities
Capital Expenditures-0.80-3.08-5.62-2.89-2.05-2.64-1.24-0.51-0.32
Acquisitions0.000.000.00296.00-144.75-214.71-75.44-48.52-52.62
Purchases of Investments-355.66-532.27-793.91-551.14-389.47-14.19-140.49-77.00-28.01
Sales/Maturities of Investments574.45700.34688.14258.03144.75214.7175.4448.5252.62
Other Investing Activities0.000.000.00-296.00144.75214.7175.4448.5252.62
Net Cash from Investing Activities218.00165.00-111.39-296.00-246.77-16.82-66.29-28.9924.29
Financing Activities
Debt Repayment0.000.000.000.000.00-16.740.008.456.89
Common Stock Issued112.1512.08353.49277.77447.28102.5427.40102.850.18
Other Financing Activities0.000.050.040.710.260.080.120.290.18
Net Cash from Financing Activities117.1112.13353.52278.47447.5485.8027.52111.597.07
Summary
Effect of Forex Changes on Cash0.46-1.670.38-2.48-0.59-0.590.41-0.610.75
Net Change in Cash56.45-5.9391.40-118.45131.2720.25-43.0047.273.39
Cash at Beginning of Period142.71148.6457.24175.6945.0124.7667.7520.4917.10
Cash at End of Period199.16142.71148.6457.24175.6945.0124.7667.7520.49
Free Cash Flow-279.92-184.46-156.73-101.32-71.55-50.76-5.87-35.23-29.04
Supplemental Disclosures
Interest Paid-----0.34---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xenon Pharmaceuticals Cash Flow

What is Xenon Pharmaceuticals's free cash flow?

Xenon Pharmaceuticals had negative free cash flow of $279.92M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$279.12M minus $799.00K of capital expenditures.

How much does Xenon Pharmaceuticals spend on capital expenditures?

Xenon Pharmaceuticals spent $799.00K on capital expenditures in fiscal 2025, compared with $3.08M a year earlier.

Does Xenon Pharmaceuticals pay dividends or buy back shares?

Xenon Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition